Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Argent Biopharma ( (AU:RGT) ) has provided an update.
Argent BioPharma has issued 21,917,267 fully paid ordinary shares and confirmed that these securities qualify for resale under the disclosure exemption provisions of section 708A(5) of Australia’s Corporations Act. The company stated it has complied with its financial reporting and continuous disclosure obligations, and that there is no undisclosed information material to assessing its financial position, prospects or the rights attached to the new shares, providing regulatory clarity and assurance for investors regarding the tradability of the stock.
The most recent analyst rating on (AU:RGT) stock is a Sell with a A$0.03 price target. To see the full list of analyst forecasts on Argent Biopharma stock, see the AU:RGT Stock Forecast page.
More about Argent Biopharma
Argent BioPharma Ltd. is a clinical-stage biopharmaceutical company focused on nano-engineered medicines that modulate the interaction between the nervous and immune systems. Its lead drug candidates, CannEpil for drug-resistant epilepsy and CimetrA for cytokine-driven inflammatory and autoimmune disorders, are supported by proprietary delivery platforms designed to enhance blood–brain and lung barrier penetration, EU-GMP manufacturing, and late-stage clinical programs targeting unmet needs in CNS and systemic inflammation.
Average Trading Volume: 195,442
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$3.03M
For detailed information about RGT stock, go to TipRanks’ Stock Analysis page.